Rchr
J-GLOBAL ID：200901022710090647
Update date: May. 01, 2020
Yukimasa Hidefumi
ユキマサ ヒデフミ | Yukimasa Hidefumi
Research field (1)：
Pharmaceuticals - chemistry and drug development
Papers (7)：
T Nishimoto, Y Amano, R Tozawa, E Ishikawa, Y Imura, H Yukimasa, Y Sugiyama. Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro. BRITISH JOURNAL OF PHARMACOLOGY. 2003. 139. 5. 911-918
T Miki, M Kori, H Mabuchi, R Tozawa, T Nishimoto, Y Sugiyama, K Teshima, H Yukimasa. Synthesis of novel 4,1-benzoxazepine derivatives as squalene synthase inhibitors and their inhibition of cholesterol synthesis. JOURNAL OF MEDICINAL CHEMISTRY. 2002. 45. 20. 4571-4580
三木隆, 郡正城, 藤島聡, 馬渕宏, 兎澤隆一, 中村昌平, 杉山泰雄, 行正秀文. Synthesis of Fused Hetero -cyclic Compounds and their Inhibitory Activities for Squalene Synthase. Bioorg. and Med. Chem. 2002. 10. 2. 385
三木隆, 郡正城, 馬渕宏, 坂野浩氏, 兎澤隆一, 中村昌平, 糸川重一, 杉山泰雄, 行正秀文. Novel 4,1-Benzoxazepine Derivatives with Potent Squalene Synthase Inhibitory Activitie. Bioorg. and Med. Chem. 2002. 10. 2. 401
樽井直樹, 中濱一雄, 長野洋一, 伊澤幹夫, 松本清治, 郡正城, 長田敏明, 三木隆, 行正秀文. Microbial Enantioselective Ester Hydrolysis for the Preparation of Optically Active 4,1-Benzoxazepine-3-acetic Acid Derivatives as Squalene Synthase Inhibitors. Chem.Phram.Bull. 2001. 50. 1. 59
ｍore...
Education (2)：
- 1979 The University of Tokyo "Graduate School, Division of Pharmaceutical Sciences"
- 1974 The University of Tokyo Faculty of Pharmaceutical Science
Professional career (1)：
薬学博士 (東京大学)
Work history (7)：
2007/04/01 - 立命館大学COE推進機構教授
2005/04/01 - 2007/03/31 医薬研究本部研究戦略部長
2001/04/01 - 2005/03/31 医薬研究本部研究推進部企画推進グループマネジャー
1999/10/01 - 2001/03/31 創薬研究本部創薬化学研究所リサーチマネジャー
1991/07/01 - 1999/09/30 研究開発本部化学研究所主任研究員
1979/04/01 - 1991/06/30 Takeda Pharmaceutical Company Limited
Ritsumeikan University Ritsumeikan-Global Innovation Research Organization Professor
Show all
Association Membership(s) (3)：
エピジェネティクス研究会
, ケミカルバイオロジー研究会
, 日本薬学会
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in
researchmap
.
For details, see here
.
Return to Previous Page
TOP
BOTTOM
